WLWenxia Li

Wenxia Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenxia Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Gao Hong

    Department of Oncology Surgery, Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine, Beijing, China

    1 shared publication
  • Haijiao Yu

    Department of Oncology Surgery, Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine, Beijing, China

    1 shared publication
  • Lei Ding

    Department of Gastrointestinal Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China

    1 shared publication
  • Ling Ma

    Department of Oncology Surgery, Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine, Beijing, China

    1 shared publication
  • Tongsheng Wang

    Department of Oncology Surgery, Beijing Shijitan Hospital, Capital Medical University, Peking University Ninth School of Clinical Medicine, Beijing, China

    1 shared publication
  • Yubing Zhu

    Beijing Shijitan Hospital Capital Medical University Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Brain metastasis from colorectal cancer: Treatment, survival, and prognosis

    by Wenxia Li, Tongsheng Wang, Yubing Zhu, Haijiao Yu, Ling Ma, Yuhan Ding, Gao Hong, Ding Lei

    To investigate the clinical characteristics, survival, prognostic factors, and treatment of brain metastasis (BM) from colorectal cancer (CRC). Twenty-one patients with BM from CRC were retrospectively reviewed. Predictive factors for BM and prognostic factors after the diagnosis of BM were examined by univariate and multivariate COX analysis. The time from the development of extracranial metastases, including lung, bone, and liver, to the occurrence of BM was recorded separately. The median overall survival time was 7 months. In univariate prognostic analysis, median survival with multimodal therapy was better than that with unimodal therapy (10 months vs 3 months, P = .000). In addition, median survival with Karnofsky performance status (KPS) < 70, 1 BM lesion, primary tumor stage of II-III, extracranial lesions < 2, and no extracranial metastasis were much better than the other groups (P < .05 of all). Although there was not a significant difference in median survival between patients receiving combination treatment with bevacizumab and those who did not, treatment with bevacizumab was associated with better survival (10 months vs 5 months, P = .436). The time intervals from bone, liver, and lung metastases to BM were 3, 6.5, and 11 months, respectively. Based on multivariate Cox analysis, KPS and treatment modalities were independent prognosis factors (P = .039 and P = .000, respectively). CRC patients with a high KPS and multimodal treatment have improved survival.